Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie’s disease: a retrospective comparative analysis (original) (raw)
Miner MM, Seftel AD. Peyronie’s disease: epidemiology, diagnosis, and management. Curr Med Res Opin. 2014;30:113–20. ArticlePubMed Google Scholar
Piraino J, Chaudhary H, Ames K, Okoye F 3rd, Sterling M, Clavell-Hernandez J, et al. A consistent lack of consistency in defining the acute and chronic phases of Peyronie’s disease: a review of the contemporary literature. Sex Med Rev. 2022;10:698–713. ArticlePubMed Google Scholar
Punjani N, Nascimento B, Salter C, Miranda E, Terrier J, Taniguchi H, et al. Predictors of Depression in Men With Peyronie’s Disease Seeking Evaluation. J Sex Med. 2021;18:783–8. ArticlePubMedPubMed Central Google Scholar
Mulhall JP, Schiff J, Guhring P. An Analysis of the Natural History of Peyronie’s Disease. J Urol. 2006;175:2115–8. ArticlePubMed Google Scholar
Weidner W, Schroeder-Printzen I, Weiske WH, Vosshenrich R. Sexual Dysfunction in Peyronie’s Disease: An Analysis of 222 Patients Without Previous Local Plaque Therapy. J Urol. 1997;157:325–8. ArticleCASPubMed Google Scholar
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology Guidelines on Sexual and Reproductive Health—2021 Update: Male Sexual Dysfunction. Eur Urol. 2021;80:333–57. ArticlePubMed Google Scholar
Fernández-Pascual E, Manfredi C, Cocci A, Quintana Franco LM, Egui Rojo MA, Carballido Rodríguez J, et al. A Novel Penile Splint as Early Traction Therapy After Grafting Techniques for Peyronie’s Disease. J Sex Med. 2020;17:1819–24. ArticlePubMed Google Scholar
Manfredi C, Arcaniolo D, Amicuzi U, Spirito L, Napolitano L, Crocerossa F, et al. Impact of extracorporeal shockwave therapy for erectile dysfunction and Peyronie’s disease on reproductive and hormonal testicular function. Andrology. 2022; https://doi.org/10.1111/andr.13240.
Ferguson JE 3rd, Carson CC 3rd. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. Arab J Urol. 2013;11:222–9. ArticlePubMedPubMed Central Google Scholar
Gonzalez-Cadavid NF, Rajfer J. Laboratory Forum: Experimental Models of Peyronie’s Disease. Implications for New Therapies. J Sex Med. 2009;6:303–13. ArticleCASPubMed Google Scholar
Chung E, DeYoung L, Brock GB. The Role of PDE5 Inhibitors in Penile Septal Scar Remodeling: Assessment of Clinical and Radiological Outcomes. J Sex Med. 2011;8:1472–7. ArticleCASPubMed Google Scholar
Ozturk U, Yesil S, Goktug HNG, Gucuk A, Tuygun C, Sener NC, et al. Effects of sildena fil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci. 2014;183:449–53. ArticleCASPubMed Google Scholar
Porst H, Burri A. Current Strategies in the Management of Peyronie’s Disease (PD)—Results of a Survey of 401 Sexual Medicine Experts Across Europe. J Sex Med. 2019;16:901–8. ArticlePubMed Google Scholar
Teloken K. Medical Management of Peyronie’s Disease: Review of the Clinical Evidence. Med Sci. 2019;7:96. CAS Google Scholar
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA.2013;310:2191.
Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002;14:245–50. ArticleCASPubMed Google Scholar
Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190:627–34. ArticlePubMed Google Scholar
Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K. Validation of the erection hardness score. J Sex Med. 2007;4:1626–34. ArticlePubMed Google Scholar
Aslam M. Introducing Kolmogorov–Smirnov Tests under Uncertainty: An Application to Radioactive Data. ACS Omega. 2020;5:914–7. ArticleCASPubMed Google Scholar
Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test. Restor Dent Endod. 2017;42:152. ArticlePubMedPubMed Central Google Scholar
Vardi Y, Levine LA, Chen J, Hatzimouratidis K, Sohn M. Is there a place for conservative treatment in Peyronie’s disease? J Sex Med. 2009;6:903–9. ArticlePubMed Google Scholar
Levine LA, Latchamsetty KC. Treatment of erectile dysfunction in patients with Peyronie’s disease using sildenafil citrate. Int J Impot Res. 2002;14:478–82. ArticleCASPubMed Google Scholar
Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, et al. Antifibrotic Role of Inducible Nitric Oxide Synthase. Nitric Oxide. 2002;6:283–94. ArticleCASPubMed Google Scholar
Valente EGA, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. l-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229–44. ArticleCASPubMed Google Scholar
Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial: ESWT and Tadalafil in PD patients. Int J Androl. 2012;35:190–5. ArticleCASPubMed Google Scholar
Dell′Atti L. Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie′s disease. Urol Ann. 2015;7:345. ArticlePubMedPubMed Central Google Scholar
Hatampour M, Sohrabi K, Mazdak H, Ghadimi K, Salehi H, Kazemi R. Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease. Am J Clin Exp Urol. 2022;10:25–30. PubMedPubMed Central Google Scholar
Gong W, Yan M, Chen J, Chaugai S, Chen C, Wang D. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling. Front Med. 2014;8:445–55. ArticlePubMed Google Scholar
Ilg MM, Stafford SJ, Mateus M, Bustin SA, Carpenter MJ, Muneer A, et al. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie’s Disease. J Sex Med. 2020;17:1848–64. ArticleCASPubMed Google Scholar
Gonzalez-Cadavid NF, Rajfer J. The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra’s advent. A personal perspective. Int J Impot Res. 2019;31:57–60. ArticleCASPubMed Google Scholar
Garaffa G, Trost LW, Serefoglu EC, Ralph D, Hellstrom WJG. Understanding the course of Peyronie’s disease. Int J Clin Pr. 2013;67:781–8. ArticleCAS Google Scholar
Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s disease. Int J Impot Res. 2002;14:414–7. ArticleCASPubMed Google Scholar
Verze P, Capece M, Creta M, La Rocca R, Persico F, Spirito L, et al. Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl. 2020;22:379. ArticleCASPubMed Google Scholar